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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYCancer pain is a debilitating disorder and a primary determinant of the poor quality of life. Here, we report a
non-vascular role for ligands of the Vascular Endothelial Growth Factor (VEGF) family in cancer pain. Tumor-
derived VEGF-A, PLGF-2, and VEGF-B augment pain sensitivity through selective activation of VEGF
receptor 1 (VEGFR1) expressed in sensory neurons in human cancer and mouse models. Sensory-neuron-
specific genetic deletion/silencing or local or systemic blockade of VEGFR1 prevented tumor-induced nerve
remodeling and attenuated cancer pain in diversemousemodels in vivo. These findings identify a therapeutic
potential for VEGFR1-modifying drugs in cancer pain and suggest a palliative effect for VEGF/VEGFR1-tar-
geting anti-angiogenic tumor therapies.INTRODUCTION
Pain is one of the most severe and common symptoms of a
variety of cancers and constitutes a primary determinant of the
poor quality of life in cancer patients (Mantyh, 2013). Bone
metastases and pancreatic ductal adeno carcinoma (PDAC)
are among the most painful forms of cancer-associated pain.
Apart from inflammatory and neuropathic components, bilateral
interactions between tumor cells and nerve cells constitute theSignificance
Several types of cancer are associated with severe pain, whic
mechanisms underlying cancer pain remain poorly understood
vessels in tumor-affected tissues, neither mutual interactions n
cancer pain. Here, we report that VEGF signaling is operationa
face. Perturbing expression, activation, or signaling of VEGFR
attenuated cancer-induced pain and tumor-induced remodelin
well as VEGF family ligands hold potential in treating cancer p
780 Cancer Cell 27, 780–796, June 8, 2015 ª2015 The Authorscornerstone of cancer (Cain et al., 2001; Mantyh, 2013; Schwei-
zerhof et al., 2009). Therefore, molecular mechanisms underlying
tumor-nerve interactions hold promise for understanding and
treating cancer-associated pain.
Although nerves and blood vessels share physical proximity
and wide set of signaling systems, regulators of vascular
remodeling have not received attention in the context of tumor-
associated pain so far. Vascular Endothelial Growth Factor
(VEGF) family of factors-mediated signaling is not only crucialh markedly reduces the quality of life in patients. Molecular
. Despite close proximity between sensory nerves and blood
or angiogenic molecules have been studied in the context of
l in nerves as well as blood vessels at the tumor-nerve inter-
1, but not of VEGFR2, in peripheral sensory nerves disrupts
g of nerves in mice in vivo. Thus, drugs targeting VEGFR1 as
ain.
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in vascular development during embryogenesis and angiogen-
esis (Olsson et al., 2006), but also operational in a variety of
non-endothelial cells, including developing neurons.
VEGF family ligands can bind to and signal via two recep-
tor tyrosine kinases, namely, VEGF receptor 1 (VEGFR1) and
VEGF receptor 2 (VEGFR2), which are highly homologous in
overall structure, but have distinct biological functions in vivo
(Ferrara et al., 2003). So far, VEGFR2 has been implicated in
all aspects of physiological and pathological angiogenesis,
e.g., in tumor angiogenesis, macular degeneration of the retina,
whereas VEGFR1 has been mostly thought to act primarily as a
decoy receptor that indirectly limits VEGFR2 activation (Ferrara
et al., 2003; Hiratsuka et al., 1998). However, there is also
evidence for VEGFR1 in transferring biological signals and
enhancing the activity of VEGFR2 in vivo (Olsson et al., 2006),
indicating that the relative contributions of VEGFR1 and VEGFR2
can vary in a context-dependent manner. Apart from VEGF-A,
other VEGF family ligands, such as placental growth factor-2
(PLGF-2) and VEGF-B, are also released in the tumor microenvi-
ronment (Fischer et al., 2008).
This study investigates biological mechanisms and thera-
peutic potential of VEGF family of factors and their signaling
mechanisms in cancer pain.
RESULTS
VEGFRs Are Expressed in Peripheral Sensory Nerves
and Their Cell Bodies in Dorsal Root Ganglia
As a first step toward characterizing a potential role for the VEGF
signaling axis in the tumor-neuro-vascular link, we analyzed the
expression of VEGFRs in mouse tissues using antibodies that
have been tested for specificity in previous studies (Stefater
et al., 2011) and in RNA interference experiments described
below.
Confocal dual immunofluorescence analysis on sections of
mouse dorsal root ganglia (DRG), where the somata of sensory
nerves reside, broadly revealed immunoreactivity for anti-
VEGFR1 distributed over thewhole cell body of sensory neurons,
whereas anti-VEGFR2 immunoreactivity was primarily localized
to the nucleus (Figures 1A and S1A). All classes of sensory neu-
rons, including peptidergic nociceptive (CGRP), non-peptidergicFigure 1. Expression of VEGFR1 and VEGFR2 in Sensory Neurons and
(A and B) Typical examples (A) and quantitative representation (B) of large- and sm
co-labeling of anti-VEGFR1 or anti-VEGFR2 with markers for subtypes of sensory
(C) Western blot analysis on mouse DRG or lysates of neuron-enriched DRG cul
(D) Co-immunostaining of anti-VEGFR1 or anti-VEGFR2 with a marker for periph
(E and F) Time course (E) and dose dependence (F) of modulation of mechanical se
of VEGF-A. Shown in (F) is the integral of entire stimulus-response frequency cu
(0.07–0.6 g) at different time points following administration of VEGF-A or saline in
of exaggerated pain sensitivity.
(G and H) Time course (G) and dose dependence (H) of effects of intraplantar inject
4 mice per dose).
(I) Analysis of Evan’s blue extravasation in mouse skin explants after cutaneous in
(J) Typical examples (upper traces) and summary (lower graph) of mean firing rate
various doses of VEGF-A in the paw skin-saphenous nerve preparation (n = at lea
images of H&E staining showing tissue morphology in sections (not adjacent, bu
(A) and (D).
*p < 0.05 as comparedwith basal, yp < 0.05 as comparedwith corresponding data
presented as mean ± SEM. Scale bars represent 50 mm in (A) and (D). See also F
782 Cancer Cell 27, 780–796, June 8, 2015 ª2015 The Authorsnociceptive (Isolectin-B4-binding), and tactile-sensitive neurons
expressing Neurofilament 200 (NF200), broadly expressed
VEGFR1 and VEGFR2 (Figures 1A, 1B, S1B, and S1C).
Western blot analyses on lysates of mouse DRG revealed a
band of the expected size for VEGFR1 at 180 kDa (Figures 1C
and S1D), but not bands corresponding to soluble (short-form)
VEGFR1. The unglycosylated form of VEGFR2 at 150 kDa
(Huang et al., 2010) was detected in DRG lysates (Figures 1C
and S1E). Expression of VEGFR1 and VEGFR2 in neuron-en-
riched cultured mouse DRG cultures was confirmed via western
blotting as well as reverse transcriptase PCR analysis (Figures
1C and S1F). Anti-VEGFR1 immunoreactivity was also observed
on sensory axons in DRG cultures (Figure S1G) as well as periph-
eral nerves in the mouse hind paw skin in vivo (Figure 1D).
In Vivo Modulation of Nociception by VEGF-A
To address potential function, we simulated VEGF receptor acti-
vation via unilateral intraplantar injections of VEGF-A in the hind
paw of mice at doses comparable to concentrations of VEGF-A
reported in the tumor microenvironment (Kut et al., 2007) and
to doses of other nociceptive mediators studied previously
(Schweizerhof et al., 2009). Although VEGF-A did not evoke
spontaneous pain behavior, mice showed a significant hyper-
sensitivity to graded von Frey mechanical stimuli and infrared
noxious heat applied to the hind pawwithin 30min of VEGF-A in-
jection, as compared with saline-treated mice (Figures 1E–1H).
VEGF-A-induced hypersensitivity was dose dependent, starting
with doses as low as 1–10 pg and reaching maximal values at
100 pg, and lasted for up to 24 hr after a single injection (Figures
1F and 1H).
Direct Modulation of Sensory Nerve Function by VEGF-A
Doses of VEGF-A that elicited marked nociceptive hyperexcit-
ability led to neither any obvious signs of vasodilation nor signif-
icant changes in neurogenic inflammation (Figure 1I), in contrast
to the positive control histamine.
Furthermore, electrophysiological single-fiber recordings on
an in vitro preparation of paw skin with attached saphenous
nerve perfused in Ringer solution, single Ad-nociceptive fibers
exposed to VEGF-A (1 to 200 ng/ml for 30 min) demonstrated
significantly higher discharge rates in response to gradedNociceptive Sensitization by VEGF-A
all-diameter sensory neurons (arrows and arrowheads, respectively) showing
neurons in sections of mouse DRG (n = 32 sections analyzed from five mice).
tures.
eral nerves (PGP9.5) in mouse paw skin biopsies.
nsitivity at the plantar surface of the hind paw following intraplantar application
rves (area under the curve [AUC]) to application of graded mechanical force
the hind paw (n = at least 4 mice per dose); an increase in the AUC is indicative
ion of VEGF-A or vehicle on pawwithdrawal latency to noxious heat (n = at least
jection of PBS (vehicle), histamine (1 mg), or various doses of VEGF-A (1–10 ng).
s of mechanoreceptive nociceptors at 30 min after exposure to vehicle (PBS) or
st 10 fibers/dose). Negative control lacking primary antibodies and bright-field
t derived from the same animals as the immunostained sections) are shown in
point for the vehicle group, ANOVA followed by post hoc Fisher’s test. Data are
igure S1.
VEGFR1-Tk -/-VEGFR1
NRP1 NRP2 NRP1 NRP2
VEGF-AVEGF-BPLGF-2
VEGFR2
VEGF-E
VEGF 
ligands
N
er
ve
 a
ct
iv
ity
(n
um
be
r o
f s
pi
ke
s/
10
s) *
0
20
40
60
80
†
vehicle 50 ng10 ng 100 ng
IgG + VEGF-A‘ anti-NRP1 + VEGF-A
anti-NRP2 + VEGF-A vehicle 50 ng10 ng 100 ng
100 pgVehicle 1 pg 10 pg 1 ng 10 ng
basal 3 hr 24 hr30 minbasal 3 hr 24 hr30 min
10
0
2
4
6
8
*† *
†
*†*
†
*
†
*
†
*
†
*
†
*
†
A
re
a 
un
de
r c
ur
ve
A
re
a 
un
de
r c
ur
ve
0
4
8
12 *†
*
†
*
†
*
† *
† *
†
*
†
*
†
*
† *
†
*
†
*
†
*
†
*
† *
†
G
La
te
nc
y 
(s
)
0
2
4
6
8
10
12
A
re
a 
un
de
r c
ur
ve
basal 3 hr 24 hr30 min
0
2
4
6
8
10
12
basal 3 hr 24 hr30 min basal 3 hr 24 hr30 min
10
0
2
4
6
8
A
re
a 
un
de
r c
ur
ve
FE
Wild-type VEGFR1-Tk -/-IgG+VEGF-A‘ anti-VEGFR1+VEGF-A
anti-VEGFR2+VEGF-A
A C
basal 3 hr 24 hr30 min
La
te
nc
y 
(s
)
basal 3 hr 24 hr30 min
0
4
8
12
* * * * * *
†
† †
0
4
8
12 * *
* * * *
†
A
re
a 
un
de
r c
ur
ve
B
A
re
a 
un
de
r c
ur
ve
basal 3 hr 24 hr30 min
***
† †
†
0
4
8
12
D
†* †*
Time after VEGF-A injection Time after VEGF-A injection Time after VEGF-A injection
Time after VEGF-A injection Time after VEGF-A injection Time after VEGF-E injection
Time after VEGF-B injection Time after PLGF-2 injection
** *
*
* * * **
* * * * ** * * *
H
Figure 2. Delineating VEGF Family Ligands and Their Receptors in Nociceptive Sensitization
(A) Schematic representation of known ligand specificity and tools employed.
(B) Effects of intraplantar delivery of neutralizing antibodies against VEGFR1 or VEGFR2 on intraplantar VEGF-A-induced mechanical hypersensitivity (left) and
thermal hyperalgesia (right) (n = 8 mice/group).
(legend continued on next page)
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mechanical stimuli than fibers exposed to the vehicle (Figure 1J),
thereby demonstrating that VEGF-A directly sensitizes nocicep-
tive axons.
VEGF-AMediates Its Pronociceptive Effects via VEGFR1
Mechanical and thermal hyperalgesia evoked by intraplantar
VEGF-Awas blocked by intraplantar pretreatment with a neutral-
izing antibody against the extracellular domain of VEGFR1,
but not by a VEGFR2-neutralizing antibody or control IgG
(Figures 2A and 2B). Consistently, VEGF-A failed to induce
mechanical sensitization of Ad-nociceptors in electrophysiolog-
ical recordings when pretreated with VEGFR1 antibody (Fig-
ure 2C). Furthermore, mice selectively lacking the tyrosine
kinase signaling domain of VEGFR1 (VEGFR1-Tk/; Hiratsuka
et al., 1998) did not develop mechanical and thermal sensitiza-
tion upon intraplantar VEGF-A injection (Figures 2D and S2A).
Thus, VEGFR1 acting via tyrosine kinase signaling, but not
VEGFR2, is required for sensitization of nociceptors by VEGF-A.
Furthermore, intraplantar injection of neutralizing antibodies
directed against NRP-1 or NRP-2, which function as VEGFR
co-receptors in some systems (Olsson et al., 2006), did not
inhibit VEGF-induced nociceptive sensitization (Figure 2E), indi-
cating that these potential co-receptors do not contribute to
VEGF-induced nociceptive sensitization.
Contributions of Other Ligands of the VEGF Family to
Nociceptive Sensitization
Intraplantar application of VEGF-E, a specific agonist at VEGFR2
(Ferrara et al., 2003) (Figure 2A), at doses up to 100 ng, did not
evoke any changes in mechanical or thermal sensitivity as
compared with saline injection (Figures 2F and S2B). In contrast,
intraplantar injection of VEGF-B or PLGF-2, which activate
VEGFR1 but not VEGFR2 (Fischer et al., 2008), evoked dose-
dependent mechanical and thermal hypersensitivity (Figures
2G, 2H, S2C, and S2D), with PLGF-2 being efficacious at doses
as low as 1 pg. Thus, diverse peripheral VEGFR1-specific ago-
nists can induce nociceptive hypersensitivity.
Signaling Mediators of VEGFR1 and Their Contribution
to Nociceptive Hypersensitivity
VEGFRs activate diverse intracellular signaling targets (Fig-
ure 3A; Olsson et al., 2006). In neuron-enriched DRG cultures,
VEGF-A induced phosphorylation of ERK1/2 (Figure 3B), indi-
cating that VEGFRs expressed on sensory neurons are function-
ally active. To test mechanistic contributions, we administered
diverse pharmacological inhibitors intraplantar, at doses re-
ported to be specific in previous in vivo studies (Malik-Hall
et al., 2005). Neither the vehicle (2% DMSO) nor any of the inhib-
itors affected nociceptive sensitivity when given in the absence
of VEGF treatment (Figure S3A). Inhibition of phospholipase
C gamma (PLCg) with U71322, the nitric oxide synthase(C) Effects of a VEGFR1-neutralizing antibody on mechanoreceptive nociceptors
(D) Effects of intraplantar injection VEGF-A (100 pg) in VEGFR1-Tk/ mice and
(E) Effects of intraplantar neutralizing antibodies against NRP1 or NRP2 on VEG
(n = 6 mice/group).
(F–H) Effects of intraplantar application of VEGF-E (F), VEGF-B (G), or PLGF-2 (H
*p < 0.05 as compared with vehicle in (D) and compared with basal in all other pan
by post hoc Fisher’s test. Data are presented as mean ± SEM. See also Figure S
784 Cancer Cell 27, 780–796, June 8, 2015 ª2015 The Authors(NOS) with L-NAME, phosphotidyl inositol 3-kinase (PI3K) with
LY294002, or the tyrosine kinase Src with PP2 either completely
abolished or strongly attenuated mechanical and thermal hyper-
sensitivity induced by VEGF-A given 30-min post-inhibitor treat-
ment (Figure 3C). PP3, the inactive analog of PP2, did not affect
VEGF-A-induced hypersensitivity (Figure S3B). Inhibition of
MEK-dependent activation of ERK1/2 via the MEK inhibitor
PD98059 significantly attenuated VEGF-A-induced mechanical
hypersensitivity, but did not affect VEGF-A-induced thermal
hyperalgesia (Figure 3C; p = 0.322). Finally, inhibition of the
p38 MAPK pathway using SB203580 affected neither VEGF-
A-induced mechanical hypersensitivity nor thermal hyperalgesia
(Figure 3C; p = 0.75).
Moreover, we observed identical modulation of PLGF-
2-induced hyperalgesia with the aforementioned inhibitors as
with VEGF-A-induced hyperalgesia (Figure S3C), indicating
common VEGFR1-mediated mechanisms.
We then addressed whether the diverse pathways involved in
VEGF-A/PLGF-2-dependent hypersensitivity all function down-
stream of VEGFR1 or act in parallel to VEGFR1. Doses of inhib-
itors that only partially inhibit VEGF-induced hypersensitivity
were identified in experiments shown in Figures 3D, S3D, and
S3E. We observed that half-maximal doses of the inhibitors of
PLCg, PI3K, or Src kinase, which represent the initiation points
of three distinct VEGFR1-activated pathways, did not add to
the pain-alleviating function of partial VEGFR1 blockade (Figures
3D, S3D, and S3E) suggesting serial, rather than parallel, rela-
tionship of these signaling cascades with VEGFR1.
Consistent with our observations with NO blockade (above),
we observed that mice lacking Prkg1, a key target of the NO-
cGMP pathway, specifically in peripheral nociceptors (Luo
et al., 2012), did not develop mechanical and thermal hyper-
sensitivity with VEGF-A (Figure 3E). We also found several
lines of evidence linking VEGF-A signaling to modulation of
TRPV1, the key final effector of thermal hyperalgesia (Bas-
baum et al., 2009). First, VEGF-A failed to evoke thermal
hyperalgesia in mice genetically lacking Trpv1, although
VEGF-A-induced mechanical hypersensitivity was fully pre-
served (Figure 3F). Second, Src, which is known to phosphor-
ylate TRPV1 and increase its membrane targeting (Basbaum
et al., 2009), was rapidly and significantly phosphorylated in
cultured sensory neurons upon treatment with VEGF-A (Fig-
ure 3G). Third, in mice injected intraplantar with VEGF-A, the
quantity of TRPV1, which could be pulled down from mem-
branes of the distal sciatic nerve segments, was significantly
increased as compared with vehicle-injected mice with a
time course consistent with VEGF-A-induced thermal hyperal-
gesia (Figure 3H). These results indicate that VEGF promotes
the trafficking and surface expression of TRPV1 in the sciatic
nerve and thereby provides a mechanistic basis for thermal
hyperalgesia. On the other hand, TRPA1 and P2X3 havein skin-nerve preparation (n = 8 fibers/group).
WT controls (n = 8 mice/group).
F-A-induced mechanical hypersensitivity (left) or thermal hyperalgesia (right)
) on mechanical sensitivity in hind paw of mice (n = at least 4 mice per dose).
els; yp < 0.05 as compared with corresponding control group; ANOVA followed
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been implicated in mechanical hypersensitivity (Brierley et al.,
2009; Jarvis et al., 2002). VEGF-A-induced mechanical hyper-
sensitivity was not affected by A317491 at the concentration
reported to be efficacious in blocking P2X3 (Jarvis et al.,
2002) (Figure S3F), but was abolished in mice lacking Trpa1
(Figure 3I). Thus, modulation of ion channels, such as
TRPV1 and TRPA1, by VEGFR1-activated signaling pathways
in peripheral neurons can account for nociceptive sensitiza-
tion evoked by VEGFR1 agonists.
Altered Expression of VEGFR1 in Sensory Nerves of
Mice Implantedwith Osteolytic Sarcoma and Its Specific
Contribution to Cancer Pain
To study tumor-associated pain, we first utilized a model based
on injection of osteolytic sarcoma cells into the intermedullary
space of the calcaneus bone of the mouse heel, which reflects
pain caused by primary sensitization of nerves in the vicinity of
the calcaneus bone and which has been reported to closely
mimic tumor-induced sensory alterations in humans (Cain
et al., 2001; Wacnik et al., 2001). Western blot analysis showed
that VEGFR1, but not VEGFR2, was significantly upregulated in
the lysates of ipsilateral L3–L4 lumbar DRGs isolated from
tumor-bearing mice as compared with sham-treated animals
(Figure 4A); no upregulation was observed in contralateral
DRGs of tumor-bearing mice (Figure S4A). Furthermore, injec-
tion of non-tumorigenic cells, such as MEFs, in the calcaneus
cavity neither led to an induction of VEGFR1 in the DRG
(Figure S4B) nor elicited nociceptive hypersensitivity (Fig-
ure S4C), indicating specificity. Interestingly, TRPV1, which
mediates VEGF-A-induced thermal hyperalgesia, (Figure 3F)
was found to be also upregulated in DRGs of cancer-bearing
mice (Figure S4D).
Furthermore, we observed that immunoreactivity for anti-
VEGFR1 was significantly increased in paw sections derived
from tumor-bearing mice as compared with sham-treated
mice, including PGP9.5-positive peripheral nerves (Figure 4B).
A key functional contribution of VEGFR1 expressed in DRG
neurons to pain was observed in experiments involving specific
lentiviral knockdown of VEGFR1 expression in L3–L4 DRGs
(Figure 4C; infection rate, 76% ± 5.3% of all DRG neurons
shown in Figure 4D; lack of infection of blood vessels in
the DRG confirmed via co-staining with anti-CD31 in Fig-
ure S4E). The efficacy of VEGFR1 downregulation in ipsilateral
L3–L4 DRGs was ascertained by western blotting (Figure 4E)
and behavioral experiments showing a marked reduction in(B) Western blots showing VEGF-A-induced phosphorylation of ERK1/2 in neuro
(C) Effects of hind-paw injection of pharmacological inhibitors on mechanical hy
injection of VEGF-A (1 ng). Shown are effects following single-dose intraplantar i
hibitor), LY294002 (1 nmole, PI3K inhibitor), PP2 (200 pmoles, Src Kinase inhibit
inhibitor), vehicle (1% DMSO).
(D) Experiments comparing the above data with effects of intraplantar combination
A-induced mechanical hypersensitivity to 0.4 g von Frey force (upper) and therm
(E and F) Effects of VEGF-A (1 ng, intraplantar) inmice lacking Prkg1 selectively in n
(Trpv1/ mice; F) (n = 6–8 mice/group).
(G) Western blots on Src phosphorylation in DRG cultures (three independent ex
(H) TRPV1 expression in membranes of distal branches of sciatic nerve in mice r
(I) Effects of VEGF-A (1 ng, intraplantar) in mice lacking Trpa1 (Trpa1/ mice) (n
*p < 0.05 as compared with basal value, yp < 0.05 as compared with correspond
mean ± SEM. See also Figure S3.
786 Cancer Cell 27, 780–796, June 8, 2015 ª2015 The AuthorsVEGF-A-induced mechanical and thermal hypersensitivity (Fig-
ure S4F). Importantly, as compared with mice expressing non-
targeting shRNA, development of tumor-induced mechanical
hypersensitivity was significantly and markedly attenuated in
mice expressing VEGFR1-shRNA (Figure 4F). Furthermore,
tumor-induced structural changes of nerves in the paw skin
overlaying the growing tumor, such as hypertrophy and
epidermal sprouting (Cain et al., 2001; Schweizerhof et al.,
2009), were evident in control shRNA-expressing mice, but
not in VEGFR1-shRNA-expressing mice (Figures 4G and 4H).
These observed differences between tumor pain and nerve re-
modeling did not result from any differences in tumor growth
(Figure S4G).
Evidence from Genetic Models and an Independent
Cancer Pain Model
To further obtain evidence from genetic models and to specif-
ically delineate the contribution of VEGFR1 expressed in noci-
ceptive neurons of the DRG, we generated a line of transgenic
mice conditionally lacking VEGFR1 in nociceptive neurons by
mating Vegfr1fl/fl mice (Ambati et al., 2006) with SNS-Cre
mice (Agarwal et al., 2004) (SNS-Vegfr1/ mice). Western
blot analysis (Figure 5A) confirmed a decrease in DRG expres-
sion of VEGFR1 (55% ± 2.8% of the value in Vegfr1fl/fl mice).
Intraplantar VEGF-A-induced mechanical and thermal hyper-
sensitivity was nearly entirely lost in SNS-Vegfr1/ mice as
compared with their WT littermates, indicating a requirement
for VEGFR1 expressed in peripheral nociceptors (Figures 5B
and 5C).
The C57Bl6 genetic background of these genetically modified
mice necessitated employing a model of cancer pain involving
isogenic tumor cells. We therefore employed a previously
described model involving subcutaneous injection of isogenic
LL2 lung carcinoma cells, which results in behavioral, structural,
and functional changes similar to the above-described calca-
neus model (Constantin et al., 2008). LL2 carcinoma-induced
mechanical hypersensitivity (Figure 5D) and tumor-induced re-
modeling of neighboring PGP9.5-positive nerves (Figures 5E
and 5F) were significantly decreased in SNS-Vegfr1/ mice as
compared with Vegfr1fl/fl mice, without any observable differ-
ence in tumor growth across genotypes (Figure 5G). Moreover,
tumor-bearing VEGFR1-Tk/ mice showed a significantly
attenuated hypersensitivity as compared with tumor-bearing
WT littermates without showing changes in tumor growth (Fig-
ures 5H and 5I).n-enriched cultured DRG neurons (n = 3 independent experiments).
persensitivity (left) and thermal hypersensitivity (right) evoked by intraplantar
njection: L-NAME (18.5 nmoles, NOS inhibitor), U71322 (20 pmoles, PLCg in-
or), PD98059 (18.7 nmoles, MEK inhibitor), SB203580 (30 nmoles, p38 MAPK
s of half-maximal doses of PLCg inhibitor and anti-VEGFR1 antibody on VEGF-
al hyperalgesia (lower).
ociceptive neurons of the DRG (SNS-Prkg1/mice; E) or inmice lacking Trpv1
periments).
eceiving intraplantar injections of VEGF-A or vehicle (n = 3 mice/group).
= 8 mice/group).
ing control, ANOVA followed by post hoc Fisher’s test. Data are presented as
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densitometric analysis (n = 3 independent experiments; *p = 0.02; Student’s t test).
(legend continued on next page)
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VEGFR1 Expression in Sensory Nerves in HumanCancer
with Pain and Its Contribution to Pain in a Mouse Model
of Pancreatic Ductal Adenocarcinoma
Given the abundance of VEGF-A and PLGF-2 in the tumor milieu
of human pancreatic carcinoma (Chang et al., 2008), we
analyzed pancreatic biopsies derived from human pancreatic
ductal adenocarcinoma (PDAC) patients and observed anti-
VEGFR1 immunoreactivity not only in blood vessels, but also in
66.3% ± 6.5% of PGP9.5-positive peripheral nerves (Figures
6A and S5A). Furthermore, anti-VEGFR1 immunoreactivity was
observed in more than 70% of each of the following fiber types
analyzed from 21 sections derived from 13 PDAC biopsies:
CGRP-positive nociceptive nerves, NF200-positive large-diam-
eter (tactile) sensory nerves, TH-expressing sympathetic nerves,
and a subpopulation of tactile sensory fibers and ChAT-express-
ing parasympathetic nerves (Figures 6B and S5B).
Importantly, nerve fibers showed a significant increase in the
intensity as well as the area of anti-VEGFR1 immunoreactivity
in biopsies of PDAC patients as compared with healthy donors
(Figures 6C and 6D), which was significantly proportional to
perceived pain intensity in PDAC patients (severe, moderate,
or mild) based upon subjective pain ratings (Figures 6E and 6F).
We then undertook functional experiments to address the role
of VEGFR1 in PDAC-related pain. First, because VEGFR1 was
observed to be broadly expressed in the DRG, including non-
nociceptive and nociceptive neurons, we generated transgenic
mice conditionally lacking VEGFR1 specifically in all neurons of
the DRG (Adv-Vegfr1/ mice) by using Advillin-Cre mice (Zur-
borg et al., 2011). Adv-Vegfr1/ mice were studied in western
blot analysis (Figure 6G; 69% ± 3.5% loss over control mice)
and showed a complete loss of mechanical and thermal sensiti-
zation with intraplantar VEGF-A (Figure 6H). Second, we estab-
lished behavioral analysis of pain associated with PDAC by
employing a model based on orthotopic implantation of mouse
PanCO2 PDAC tumor cells or vehicle (sham) in the pancreas of
C57Bl6 mice (Zhu et al., 2008). Upon testing sensitivity to
abdominal application of low force-von Frey hairs, we observed
that post-operative pain was comparable across PanCO2-in-
jected Adv-Vegfr1/ mice and control littermates (also evident
in sham-injected mice; data not shown), but tumor-induced
mechanical hypersensitivity starting from day 13 (specific to
PanCO2-injected mice) was significantly reduced in Adv-
Vegfr1/ mice as compared with control littermates (Figure 6I).
Importantly, SNS-Vegfr1/mice demonstrated a similar degree
of attenuation of tumor-induced nociceptive hypersensitivity
as Adv-Vegfr1/ mice (Figure 6I), indicating that VEGFR1 ex-
pressed on nociceptive neurons can largely account for the
key role observed for VEGFR1 to tumor pain. Pancreatic tumor
size was not significantly different across genotypes (Figure 6J).(B) Typical examples and quantitative summary of VEGFR1 expression in PGP9
sham hind paw (n = 6 mice/group). Negative controls for immunostaining and H&
judge morphology. epi, epidermis; der, dermis.
(C and D) Whole-mount images (C) or cryosection (D) of a DRG 3 weeks after inj
(E) Western blot analysis of VEGFR1 expression in L3–L4 DRGs injected ipsilater
(F–H) Tumor-induced mechanical hypersensitivity (F) and tumor-induced hypertro
PGP9.5 (G and H) in mice injected with lenti-VEGFR1-shRNA as compared with
*p < 0.05 as compared with sham in (B), (H) and compared with basal in (F); yp < 0
Fisher’s test. Scale bars represent 50 mm in (B), (D), and (G) and 250 mm in (C). D
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Cancer Pain and Their Functional Contributions
ELISA-based analysis demonstrated a high level of availability of
VEGF-A as well as PLGF-2 in paw tissue surrounding the tumor,
including sensitized skin, in the calcaneus osteolytic sarcoma
implantation model (Figure 7A). Injection of specific function-
blocking antibodies directed against VEGF-A or PLGF-2 in the vi-
cinity of the tumor led to a strong reduction in tumor-associated
mechanical hypersensitivity (Figure 7B). Anti-VEGF-A, but not
anti-PLGF-2, significantly reduced tumor growth at the doses
tested (Figure 7B). Moreover, an antibody neutralizing VEGF-B
significantly reduced tumor-induced hypersensitivity, but to a
lesser degree than anti-VEGF-A or anti-PLGF-2 (Figure S6A),
without affecting tumor growth (Figure S6B). Thus, diverse
VEGFR1 ligands are locally available in the tumor milieu and
contribute collectively to tumor-induced hypersensitivity.
We further employed twobiological tools to bindand sequester
VEGFR1 ligands and/or prevent them from binding to VEGFR1.
First, in comparison to injection of a control Fc protein, local injec-
tion of soluble form of VEGFR1 lacking the C terminus and the
kinase domain (sFlt1) (Ferrara et al., 2003) blocked VEGF-A-
induced hyperalgesia (Figures S6C and S6D), significantly
attenuated tumor-associated hypersensitivity (Figure 7C), and
reduced tumorgrowth toa small but significant extent (Figure 7C).
Second, we employed a small anti-VEGFR1 hexapeptide
(GNQWFI, anti-Flt1 peptide), whichprevents bindingof all ligands
to the extracellular domain of VEGFR1 (Bae et al., 2005). How-
ever, because this peptide has only been used in a few in vivo
studies so far (Bae et al., 2005), we validated in vivo efficacy by
testing impact on VEGFR1 activation judged via tyrosine phos-
phorylation on VEGFR1 on position 1213, whichwas significantly
enhanced in tumor-bearing paw compared with sham-treated
paw (Figure 7D). Upon administration of a single intraplantar
injection of the anti-Flt1 peptide at a dose of 25 mg, tumor-asso-
ciated tyrosine phosphorylation of VEGFR1 was significantly
attenuated for 24 hr (Figure 7D). This dose of the anti-Flt1 peptide
blocked intraplantar VEGF-A-induced nociceptive hypersensitiv-
ity (Figures S6E andS6F) and also significantly attenuated tumor-
associatedmechanical hypersensitivity when given over multiple
timepoints (Figure 7E). Thesedifferencesdidnot arise fromdiffer-
ences in tumor growth between groups (Figure 7E). Furthermore,
infiltration of GR-1-positive neutrophils in the tumor vicinity was
not significantly different across the above groups (Figure S6G).
Effects of Local Immunological Blockade of VEGFR1 or
VEGFR2 Signaling on Cancer Pain and Nerve
Remodeling
Given their growing therapeutic potential in cancer treat-
ment, we tested immunologicals for efficacy in repressing.5-positive peripheral nerves overlying bone metastases in tumor-affected or
E-stained sections from same animals (not adjacent sections) are included to
ection of lentivirions expressing EGFP and shRNA.
ally (ipsi) with lentivirions, using contralateral DRGs as control.
phy and sprouting of epidermal sensory nerves expressing the marker protein
lenti-non targeting shRNA in the DRG (n = 5 mice/group).
.05 as compared with lenti-non-targeting control; ANOVA followed by post hoc
ata are presented as mean ± SEM. See also Figure S4.
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VEGFR1-mediated nociceptive hypersensitivity and tumor-
associated pain as well as the accompanying nerve remodeling.
First, in the calcaneus osteolytic sarcoma implantation
model, local administration of anti-VEGFR1, but not anti-
VEGFR2 or control IgG, in the vicinity of the tumor on days 1,
3, 5, 7, 9, 11, and 13 post-tumor cell implantation significantly
blocked tumor-induced mechanical hypersensitivity (Figure 8A)
and significantly attenuated tumor-associated sprouting and
hypertrophy of PGP9.5-positive nerve fibers in the epidermis
(Figure 8B). No differences were observed with respect to local
tumor growth or local inflammation with anti-VEGFR1 at the
dose applied (Figures S7A–S7C). Interestingly, however, in
tumor-bearing mice, locally administered anti-VEGFR2 sup-
pressed tumor angiogenesis to a much stronger extent than
anti-VEGFR1, as compared with mice that received control
IgG (Figure S7D), indicating that VEGFR1 and VEGFR2 mediate
differential aspects of remodeling in the tumor-nerve-blood
vessel milieu.
Efficacy of Systemically Administered Anti-VEGFR
Immunologicals in aModel of Cancer-InducedBonePain
as a Potential Therapeutic Strategy
Finally, we endeavored to test the efficacy of systemically
administered immunologicals using a clinically relevant model
that simulates pain induced by metastases in large skeletal
bones in cancer patients (Bloom et al., 2011; Mantyh, 2013).
Upon unilateral implantation of mammary carcinoma cells in
the intermedullary cavity of mouse femur bone, mice not only
show nociceptive hypersensitivity in the ipsilateral hind paw
(secondary hyperalgesia), but also signs of spontaneous
ongoing pain, such as lifting or flicking of the affected limb and
altered gait (Bloom et al., 2011; Mantyh, 2013; Movies S1, S2,
S3, and S4). High-quality function-blocking antibodies against
VEGFR1 (MF-1) or VEGFR2 (DC101), which have been validated
in vivo previously upon intraperitoneal delivery inmice (Carmeliet
et al., 2001; Fischer et al., 2007), were administered at every
3 days until day 29 post-tumor cell implantation.
Systemically delivered MF-1 strongly attenuated the develop-
ment of nociceptive hypersensitivity to von Frey force applied
to the ipsilateral hind paw (Figure 8C) as compared with control
IgG or DC101 application. Similar results were observed with
respect to tumor-induced spontaneous nocifensive pain
behavior (Figure 8D; Movies S1, S2, S3, and S4). At late stages
only (30-days post-tumor implantation), a partial suppressionFigure 6. Role of VEGFR1 in Pain Associated with PDAC
(A and B) Examples (A) and quantitative analyses (B) of nerves (arrows) showing
indicate blood vessels. n = 21 sections analyzed from 13 biopsies.
(C and D) Typical examples (C) and quantitative summary (D) of VEGFR1 express
(n = 95 sections from 30 patients and 7 donors).
(E and F) Typical examples (E) and quantitative summary (F) of the relation between
reported by the patients (n = 79 sections from 30 patients).
(G) Western blot analysis of VEGFR1 expression in DRGs of mice with Advillin-Cre
(H) VEGF-A-induced mechanical hypersensitivity (left) and thermal hyperalgesia
(I and J) Comparison of early post-operative pain (red arrow), tumor-associated h
integral of responses to all von Frey forces tested (right) and tumor mass (J) betw
8 mice/group).
*p < 0.05, t test in (D) and (F). *p < 0.05 as comparedwith basal in (H) and (I); ANOVA
with corresponding control group, ANOVA for random measures followed by pos
Data are presented as mean ± SEM. See also Figure S5.of nociceptive hypersensitivity or spontaneous pain behavior
was observed with the systemically delivered DC101.
Furthermore, mice receiving systemic treatment with the MF1,
but not DC101 or control IgG, showed a marked reduction in
bone metastases-induced sprouting of periosteal nerves (Fig-
ure 8E). Both clones significantly reduced the growth rate of
mammary carcinoma cells in mice upon systemic delivery (Fig-
ure S7E); however, DC101 suppressed tumor growth to a higher
extent than MF1, indicating again a mechanistic dichotomy of
VEGFR2 and VEGFR1 in the modulation of tumor growth and
nociceptive sensitization in cancer pain.
DISCUSSION
VEGF signaling has already gained major significance in the
pathophysiology and therapy of cancer; this study extends its
functional and therapeutic repertoire beyond tumor angiogen-
esis and metastases to the avenue of cancer pain by acting at
the interface between tumor cells, blood vessels, and nerves
to regulate pain sensitivity via functional and structural modula-
tion. We present several converging lines of evidence showing
that peripherally acting VEGF ligands induce nociceptive sensi-
tization via direct effects on peripheral nerves, rather than non-
neuronal modulation, and that the contribution of nociceptors
is paramount.
Our analyses indicate that VEGFR1 activation in sensory neu-
rons triggers both functional and structural remodeling. VEGFR1
activated diverse kinases, such as PLCg, PI3K, and Src kinase,
that sensitize transducers of heat, pressure, and chemical stimuli
in nociceptive terminals, such as TRPV1 and TRPA1, as well as
amplifiers of afferent excitability, such as Nav1.8 (Basbaum
et al., 2009; Hucho and Levine, 2007). Our observation that
VEGFR1 modulates TRPV1 function via Src and promotes its
trafficking in peripheral nerves is interesting because TRPV1
senses local acidosis and algogens, such as eicosanoids and
lipids, which are abundant in the tumor environment (Mantyh,
2013).
Our findings on the role of VEGFR1 in cancer-related structural
remodeling of nerves and its upregulation in sensory nerves
within the tumor milieu in mouse models and PDAC patients in-
dicates a strong link between VEGF signaling in sensory nerves,
structural remodeling, and pain; however, a causal relationship
between nerve sprouting and pain in cancer cannot yet be
derived. Of note, VEGF-mediated signaling converges with thatanti-VEGFR1 immunoreactivity in PDAC biopsies from patients. Arrowheads
ion in PGP9.5-positive nerves in human PDAC and pancreas of healthy donors
VEGFR1 immunoreactivity in human PDAC biopsies and subjective pain rating
-mediated pan-DRG VEGFR1 deletion (Adv-Vegfr1/) and controls (Vegfr1fl/fl).
(right) in Adv-Vegfr1/ and Vegfr1fl/fl mice (n = at least 4 mice/group).
ypersensitivity (blue arrow) to 0.008 g of abdominal von Frey application (I) and
een Adv-Vegfr1/mice, SNS-Vegfr1/mice, and Vegfr1fl/fl mice (n = at least
for repeated-measures followed post hoc Fisher’s test; yp < 0.05 as compared
t hoc Fisher’s test. Scale bar represents 100 mm in (A) and (C) and 50 mm in (E).
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of NGF, another major player in nerve remodeling (Mantyh et al.,
2011), on common intracellular effectors, e.g., the PI3K-Akt
pathway.
Remarkably, our results suggest a functional dichotomy of
the two main lines of VEGF signaling in sensory nerves and
blood vessels. Although VEGFR2 regulates tumor angiogenesis
(Ferrara et al., 2003), it does not contribute to sensitization of
nerves: this may be accounted for by the observed nuclear
localization for VEGFR2 in sensory neurons, the higher level
of distribution of VEGFR1 at the cell surface of sensory neurons
and the 10-fold higher affinity of VEGF-A for VEGFR1 over
VEGFR2.
The efficacy of targeting PLGF-2 in cancer therapy is a much
debated topic of acute interest and high relevance in the
cancer field (e.g., Bais et al., 2010; Van de Veire et al., 2010).
Our observation that PLGF-2 is even more potent and effica-
cious than VEGF-A in inducing nociceptive hypersensitivity
may stem from proposed differences in the VEGFR1 binding/
activation mode between these agonists (Carmeliet et al.,
2001). Furthermore, on the background of reports on syner-
gistic activation of VEGFR1 by PLGF-2 and VEGF-A in angio-
genesis and plasma extravasation (Carmeliet et al., 2001), our
results suggest that a co-release of these factors in the tumor
microenvironment may cooperate in evoking exaggerated
pain sensitivity.
Administration of Bevacizumab, a humanized monoclonal
immunological sequestering VEGF-A, enhances the quality of
life in cancer patients (Garassino et al., 2007; Johnson et al.,
2004), which would be generally consistent with this study
since pain is an important parameter for quality of life in cancer
patients. Our results therefore suggest that pain should be
directly and objectively tested as a clinical end point in clinical
studies involving VEGF-targeted therapies in cancer patients.
Furthermore, given our results showing roles for VEGF-A,
PLGF-2, and VEGF-B in bone metastatic pain, we suggest
that targeting individual ligands may be less efficacious than
targeting the receptor (VEGFR1) they converge upon. More-
over, our results on the efficacy of locally applied small anti-
Flt1 peptide in tumor pain models provide scope for limiting
side effects attributed to immunologicals and global interven-
tion in VEGF signaling.
Taken together, our findings from several animal models of
cancer pain, human cancer material, and mechanistic analyses
indicate therapeutic potential for VEGFR1-modifying drugs in
cancer pain and suggest that combined targeting of VEGFR1
and VEGFR2 may enable modulation of distinct aspects of
cancer at the tumor-neuro-vascular interface.Figure 7. Role of Diverse VEGFR1 Ligands and Sequestering Agents in C
(A) ELISA-based analysis of VEGF-A and PLGF-2 in hind paw (n = 4 mice each).
(B) Effects of intraplantar application of VEGF-A-sequestering antibody (upper),
chanical hypersensitivity and tumor growth (n = at least 6 mice/group).
(C) Effects of intraplantar application of soluble-VEGFR1 (sFlt1) or control protein
group).
(D) Typical example (left) and densitometric quantification (right) of tyrosine phosp
modulation by local application of anti-Flt1 or reverse peptide 8 days post-tumo
(E) Effects of intraplantar application of anti-Flt1 or reverse peptide on tumor-ind
*p < 0.05, ANOVA followed post hoc Fisher’s test as compared with basal, ANOV
with corresponding control group and #p < 0.01 as compared with reverse peptid
are presented as mean ± SEM. See also Figure S6.EXPERIMENTAL PROCEDURES
Sensory-Neuron-Specific Knockout Mice
Mice lacking VEGFR1 in a sensory neuron-specific manner were generated by
matingmice carrying floxed alleles of the Flt1 (vegfr1) gene (Ambati et al., 2006)
with mice expressing the Cre recombinase selectively in nociceptors (SNS-
Cre; Agarwal et al., 2004) or with mice expressing the Cre recombinase selec-
tively in all neurons of the DRG (Advillin-Cre; Zurborg et al., 2011).
Antibodies Used for Immunohistochemistry and Western Blotting
The following are used for immunohistochemistry on mouse paw skin: PGP9.5
(1:1000, Ultraclone), and on human pancreatic biopsies: (1) anti-PGP9.5
(1:1000; Ultraclone), (2) anti-VEGFR1 (1:200, #AF321, R&D Systems), (3)
anti-VEGFR2 (1:200; MAB3571; R&D Systems), (4) anti-choline acetyl trans-
ferase (1:400; Neuromics), (5) anti-tyrosine hydroxylase (#22941; Immunostar),
(6) anti-CGRP (1:300; 24112; Immunostar), (7) anti-neurofilament-200 antibody
(1:500, #N4142; Sigma Aldrich), and (8) anti-CD31 (clone JC70A, #M0823;
DAKO Deutschland GmBH).
The following are used for immunofluorescence analysis on mouse DRGs:
anti-VEGFR1 (1:100; MAB471; R&D Systems); anti-VEGFR2 (1:100; sc-505;
Santa Cruz Biotechnology SCBT), anti-CGRP (1:300; 24112; Immunostar)
and biotinylated IB4 (1:200; B-1205; Vector), anti-neurofilament-200 antibody
(1:500, #N2912, #N4142; SigmaAldrich), anti-CD31 (1:500, #550274; BDPhar-
Mingen) (see Supplemental Experimental Procedures); western blotting: anti-
VEGFR1 (1:1000; #1301-1; Epitomics), anti-VEGFR2 (1:1000; sc-505; SCBT),
a phospho-VEGFR1 (Tyr1213) antibody (07-758; Merck Millipore), anti-Src
and anti-phospho-Src antibodies (1:1000; #2208; #2101; Cell Signaling Tech-
nologies), anti-TRPV1 (1:2500; sc-12498; SCBT), and anti-alpha-tubulin
(1:2500, T9026; Sigma Aldrich).
Four Independent Mouse Models of Cancer-Associated Pain
All animal experiments were approved by the local governing board on animal
protection laws (Regierungspra¨sidium) and were performed in accordance
with their regulatory standards. All behavioral measurements were done in
awake, unrestrained, age-matched adult (3 months old) male mice.
(1) Osteolytic sarcomamodel of cancer pain in the calcaneus bone: osteo-
lytic sarcoma cells NCTC clone 2472 (National Collection of Type
Cultures clone 2472; ATCC) (2 3 106 per injection) were unilaterally
injected into and around the calcaneus bone of C3H/HeNCrl mice
(Wacnik et al., 2001). Blocking antibodies, soluble VEGFR1 (sFlt1),
anti-Flt1 peptide, or their respective controls were injected ipsilaterally
intraplantar in the vicinity of the calcaneus bone. Antibodies against
VEGFR1 (AF471; R&D Systems), VEGFR2 (AF644; R&D Systems),
PLGF-2 (MAB465; R&D Systems), VEGF-B (AF590; R&D Systems),
VEGF-A (AF-493-NA; R&D Systems) or normal goat IgG or rat IgG
(AB-108-C, MAB006; R&D Systems) (each 5 mg diluted in 25 ml) were
applied on days 1, 3, 5, 7, 9, 11, and 13 post-tumor implantation. An
anti-Flt1 peptide, GNQWFI (25 mg diluted in 25 ml, RB-PP-0245; Ray
Biotech), reverse peptide sequence, IFWQNG (25 mg diluted in 25 ml;
Ray Biotech), soluble VEGFR1 (sFlt-1, SFC-M06; 10 mg diluted in
25 ml; Reliatech), or mouse IgG-Fc fragment (10 mg diluted in 25 ml,
4460-MG; R&D Systems) were administered every other day from
days 1 to 13 post-tumor implantation.ancer Pain in the CalcaneusOsteolytic Sarcoma ImplantationModel
PLGF-2-sequestering antibody (lower), or control IgGs on tumor-induced me-
on tumor-induced mechanical hypersensitivity and tumor size (n = 5–6 mice/
horylation of VEGFR1 inmouse hind paw in sham or tumor-bearing mice and its
r implantation (n = 3 mice/group).
uced mechanical hypersensitivity and tumor growth (n = 6–8 mice).
A of repeated-measures performed in (B), (C), and (E); yp < 0.05 as compared
e in (D), ANOVA for random measures followed by post hoc Fisher’s test. Data
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Figure 8. Effects of Local or Systemic Immunological Blockade of VEGFR1 or VEGFR2 on Cancer Pain
(A and B) Effects of a regime of local, intraplantar injections of either IgG or anti-VEGFR1 or anti-VEGFR2 antibodies (5 mg/dose) on tumor-induced mechanical
hypersensitivity (A) and tumor-induced hypertrophy and sprouting of PGP9.5-immunoreactive epidermal sensory nerves (B) in the calcaneus osteolytic sarcoma
implantation model (n = at least 6 mice/group).
(legend continued on next page)
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(2) Femur model of cancer-induced bone pain: Cells of the murine osteo-
lytic breast carcinoma cell line, 4T1-Luc, which express the luciferase
reporter gene (Srivastava et al., 2014) or PBS (sham) were inmice of the
Balb/c strain directly into the intermedullary space of the mouse femur
following an arthrotomy (1.5 3 105 cells/injection), as described previ-
ously (Bloom et al., 2011). Different cohorts of mice treated with MF-1
(Eli Lilly and Company), DC101 (Eli Lilly and Company), or control IgG
(DivBioScience) were injected systemically (each 40 mg/kg body
weight) every third day over 4 weeks post-tumor implantation (Carme-
liet et al., 2001; Fischer et al., 2007).
(3) In gene-targeted mice, we injected lung carcinoma cells of the ETCC
clone 1642 (European Collection of Cell Cultures), isogenic with
the C57Bl6 mouse strain, subcutaneously in the plantar and dorsal
side of the mouse hind paw (7 3 105 cells/injection) (Constantin
et al., 2008).
(4) Orthotopic injection model of PDAC: Mouse pancreatic carcinoma
cells (PanCO2, 5000 cells resuspended in 5 ml) or PBS (sham) were
injected into the pancreas of deeply anesthetized C57Bl6 mice (Zhu
et al., 2008), keeping the abdominal surgical cut to aminimum. Abdom-
inal sensitivity to graded von Frey stimuli was assessed in awake, freely
moving mice, and withdrawal behavior was analyzed.
In all models, all behavioral analyses were performed in a blinded manner;
i.e., the investigator was unaware of the experimental condition tested.
Ethics Statement for Human Tissues
The use of archived pancreatic tissueswas approved by the institutional review
board, andwritten informedconsent was obtained from the patients prior to the
surgical procedure (ethics committee, University of Heidelberg; #301/2001).
Additional details on experimental procedures are given in Supplemental
Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and four movies and can be found with this article online at
http://dx.doi.org/10.1016/j.ccell.2015.04.017.
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